High-validity
real-world evidence at scale
Support clinical assertions that impact development, launch, and adoption
of therapies with credible data across all therapeutic classes.
New times call for a powerful platform
For biopharma decision-makers, Verantos is making what seemed impossible, possible. Our high-validity RWE platform combines deep phenotyping — structured and unstructured data from electronic health records (EHR), artificial intelligence (AI), and accuracy determination — with linkage to exposure and outcomes data to answer today’s most challenging clinical questions.
Our Awards
Meet increasing RWE demands
High-validity RWE – utilizing the entire patient record, deep phenotyping, AI-generated insights, and linked exposures and outcomes – makes it possible to understand how patient characteristics and behaviors affect health outcomes to predict the progression of a disease and a patient’s responses to therapy while also increasing the efficiency of R&D investments and accelerating time to market.
Get out of the danger zone
Studies based on traditional RWE leave franchises vulnerable to regulatory and market access concerns and commercial delay. High-validity studies run on our advanced RWE platform provide accurate and believable evidence, enabling regulatory and reimbursement approvals. It is worth investing now in the RWE platform of the future.
Our Partners
